Skip to content
HowShorted

LIGAND PHARMACEUTICALS INC short interest in 2020

In 2020, LIGAND PHARMACEUTICALS INC's disclosed short interest ran from 44.13% of shares outstanding on 15 Jan 2020 to 61.59% on 31 Dec 2020, a change of +17.46 percentage points. The year's high was 66.81% on 30 Oct 2020 and its low 43.69% on 14 Feb 2020, averaging 56.48% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 62.97 days on 31 Aug 2020. Full history: LIGAND PHARMACEUTICALS INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for LIGAND PHARMACEUTICALS INC in 2020

2020 in figures

Start of year
44.13% (15 Jan 2020)
End of year
61.59% (31 Dec 2020)
Change
+17.46 pp
High
66.81% (30 Oct 2020)
Low
43.69% (14 Feb 2020)
Average
56.48%
Highest days to cover
62.97 (31 Aug 2020)
SEC filings marked
10

Every report in 2020

LIGAND PHARMACEUTICALS INC short interest in 2020
SettlementShort interestDays to coverFilings since previous
15 Jan 202044.13%26.49
31 Jan 202043.74%27.84
14 Feb 202043.69%24.74results (8-K)
28 Feb 202047.90%13.4310-K filed
13 Mar 202053.95%14.08
31 Mar 202056.07%13.05
15 Apr 202057.25%18.68results (8-K)
30 Apr 202055.63%24.73
15 May 202058.85%25.09results (8-K), 10-Q filed
29 May 202057.68%38.17
15 Jun 202058.89%27.68
30 Jun 202056.04%26.14
15 Jul 202054.99%37.54
31 Jul 202053.22%49.80
14 Aug 202055.53%35.60results (8-K), 10-Q filed
31 Aug 202056.07%62.97
15 Sep 202057.69%36.09
30 Sep 202061.21%31.79
15 Oct 202063.59%53.15
30 Oct 202066.81%21.29results (8-K), results (8-K)
13 Nov 202066.07%35.4910-Q filed
30 Nov 202063.02%43.23
15 Dec 202062.03%31.68
31 Dec 202061.59%40.76

See also: LIGAND PHARMACEUTICALS INC's full history · most shorted US stocks of 2020 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.